Skip to content

November sales inch up at Rite Aid

Rite Aid Corp. posted a slight gain in comparable-store sales for November. Rite Aid said Thursday that for the five weeks ended Nov. 28, comp-store sales edged up 0.9% year over year, compared with a 1% same-store sales increase for October (covering a four-week period).

Table of Contents

CAMP HILL, Pa. — Rite Aid Corp. posted a slight gain in comparable-store sales for November.

Rite Aid said Thursday that for the five weeks ended Nov. 28, comp-store sales edged up 0.9% year over year, compared with a 1% same-store sales increase for October (covering a four-week period).

In November, same-store sales rose 1.2% in the front end and 0.7% in the pharmacy. Rite Aid said comparable pharmacy sales reflect a negative impact of 267 basis points from introductions of new generic drugs.

Prescription count at comparable stores grew 0.8% versus the year-ago period.

Overall drug store sales for November dipped 0.6% to $2.556 billion from $2.571 billion a year earlier. Prescription sales represented 69.2% of drug store sales.

For the 13-week fiscal 2016 third quarter ended Nov. 28, same-store sales were up 0.9%, including gains of 0.3% in the front end and 1.2% in the pharmacy. Prescriptions filled at comparable stores increased 0.2%.

Drug store sales for the quarter totaled $6.701 billion, up 0.8% from $6.651 billion in the prior-year period. Prescription sales accounted 69.9% of drug store sales.

Rite Aid said comp-store sales for the 39-week fiscal year-to-date period ended Nov. 28 gained 1.9%, with increases of 0.4% in the front end and 2.6% in the pharmacy. Prescription count at comparable stores was up 0.6%.

Total drug store sales for the 39 weeks rose 1.8% to $19.906 billion from $19.553 billion a year earlier. Prescription sales represented 69.5% of drug store sales in the period

As of Nov. 28, Rite Aid operated 4,560 drug stores, compared with 4,572 stores a year ago.

Comments

Latest

FMI: Private brands take hold

FMI: Private brands take hold

Perceptions around private brands have changed; they are no longer seen merely as generics or national brand equivalents, Doug Baker, vice president, industry relations at FMI, said in releasing the report, titled “The Power of Private Brands 2024.”